Comparative Pharmacology
Head-to-head clinical analysis: CEPHALEXIN versus KEFTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHALEXIN versus KEFTAB.
CEPHALEXIN vs KEFTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting cell wall cross-linking, leading to cell lysis and death.
Cephalexin binds to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
Oral: 250-1000 mg every 6 hours; maximum 4 g/day.
Cefuroxime axetil (KEFTAB) 250-500 mg orally twice daily for 7-10 days. For uncomplicated urinary tract infections: 250 mg twice daily; for acute otitis media: 500 mg twice daily.
None Documented
None Documented
Clinical Note
moderateCephalexin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cephalexin."
Clinical Note
moderateCephalexin + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Cephalexin."
Clinical Note
moderateCephalexin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cephalexin."
Clinical Note
moderateCephalexin + Sulfisoxazole
0.5-1.2 hours in normal renal function; prolonged to 5-30 hours in severe renal impairment (CrCl <10 mL/min)
0.8-1.2 hours (prolonged to 6-8 hours in renal impairment; requires dose adjustment for CrCl <50 mL/min)
Renal: 80-90% unchanged by glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Renal: 90-95% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The metabolism of Sulfisoxazole can be decreased when combined with Cephalexin."